The Higher Education Commission (HEC) has launched a three-day training program on Applied Artificial Intelligence for university administrators, aiming to improve management, efficiency and digital ...

ISLAMABAD - Higher Education Commission (HEC) of Pakistan, through its National Academy of Higher Education (NAHE), has announced a pioneering 3-day training programme on “Applied Artificial ...

Higher Education Commission (HEC) of Pakistan, through its National Academy of Higher Education (NAHE), has announced a pioneering 3-day training programme on “Applied Artificial Intelligence for ...

RAS Commander MCP provides bounded, read-only information from HEC-RAS project and plan text through the public RAS Commander Python API. It requires no HEC-RAS executable. The fuller modeling, ...

Ras Al Khaimah: With wide participation from universities and local and international educational institutions, His Excellency Mohamed Mosbbeh Al Nuaimi, Chairman, Ras Al Khaimah Chamber of Commerce ...

BANDAR LAMPUNG (Lampungpro.co) : Politeknik Negeri Lampung (Polinela) memperkuat kapasitas sumber daya manusia akademik melalui peningkatan kompetensi yang relevan dengan perkembangan teknologi dan ...

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...

Islamabad (GNP): National Academy of Higher Education (NAHE), Higher Education Commission (HEC) Pakistan, has concluded a three-day Tier-I Faculty Training Programme on Artificial Intelligence (AI) ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...

The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...